Pasithea Financial Statements From 2010 to 2024

KTTA Stock  USD 5.14  0.03  0.59%   
Pasithea Therapeutics financial statements provide useful quarterly and yearly information to potential Pasithea Therapeutics Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pasithea Therapeutics financial statements helps investors assess Pasithea Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pasithea Therapeutics' valuation are summarized below:
Gross Profit
-2.2 K
Market Capitalization
5.4 M
Enterprise Value Revenue
277.4414
Revenue
486.6 K
Earnings Share
(13.74)
We have found eighty-five available trending fundamental ratios for Pasithea Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Pasithea Therapeutics recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of June 19, 2024, Market Cap is expected to decline to about 17.7 M. The current year's Enterprise Value is expected to grow to about (17.5 M)

Pasithea Therapeutics Total Revenue

362,332

Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 680.9 K, Interest Expense of 224 or Other Operating Expenses of 9.9 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.37. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Pasithea Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets34.3 M26.1 M10.8 M
Slightly volatile
Other Current Liabilities2.7 M2.6 M491.1 K
Slightly volatile
Total Current Liabilities1.4 M2.6 M426.5 K
Slightly volatile
Total Stockholder Equity32.3 M23.4 M10.2 M
Slightly volatile
Net Tangible Assets62.1 M59.1 M15.1 M
Slightly volatile
Accounts Payable2.7 M2.6 M491.1 K
Slightly volatile
Cash28.2 M16.3 M8.9 M
Slightly volatile
Cash And Short Term Investments28.2 M16.3 M8.9 M
Slightly volatile
Common Stock Shares Outstanding1.2 M1.2 M827.2 K
Slightly volatile
Liabilities And Stockholders Equity34.3 M26.1 M10.8 M
Slightly volatile
Other Current Assets364.9 K361.1 K115.7 K
Slightly volatile
Other Stockholder Equity48 M58.7 M15 M
Slightly volatile
Total LiabilitiesM2.7 M625.5 K
Slightly volatile
Net Invested Capital32.3 M23.4 M10.2 M
Slightly volatile
Total Current Assets28.7 M16.7 MM
Slightly volatile
Capital Stock98.810413.3 K
Slightly volatile
Net Working Capital27.3 M14.1 M8.6 M
Slightly volatile
Common Stock98.810413.3 K
Slightly volatile
Other Liabilities1.2 M1.3 M1.4 M
Slightly volatile
Property Plant And Equipment Gross231.8 K244 K134.5 K
Slightly volatile
Property Plant Equipment16.1 K18.1 K19.7 K
Slightly volatile
Short and Long Term Debt Total77.6 K81.7 K813.9 K
Slightly volatile
Net Receivables38.5 K40.5 K267.1 K
Slightly volatile
Short Term Debt138 K81.7 K242.8 K
Slightly volatile
Intangible Assets6.6 M7.9 M8.4 M
Slightly volatile
Other Assets0.80.90.98
Slightly volatile

Pasithea Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization680.9 K648.5 K138.9 K
Slightly volatile
Other Operating Expenses9.9 M16 M3.1 M
Slightly volatile
Total Operating Expenses9.6 M15.3 MM
Slightly volatile
Selling General Administrative8.3 B7.9 B1.1 B
Slightly volatile
Total Revenue362.3 K559.5 K105.9 K
Slightly volatile
Cost Of Revenue680.9 K648.5 K110 K
Slightly volatile
Reconciled Depreciation543.5 K517.7 K74 K
Slightly volatile
Selling And Marketing Expenses4.3 B7.9 B815.7 M
Slightly volatile

Pasithea Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation680.9 K648.5 K91.9 K
Slightly volatile
Capital Expenditures32.6 K34.3 K164.2 K
Slightly volatile
End Period Cash Flow28.2 M16.3 M8.9 M
Slightly volatile
Change To Liabilities532.1 K506.8 K135.3 K
Slightly volatile
Stock Based Compensation696.1 K592.3 K518.6 K
Slightly volatile
Begin Period Cash Flow31.6 M33.1 MM
Slightly volatile
Issuance Of Capital Stock31 M24.4 M45.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio36.3938.312.2 K
Slightly volatile
PTB Ratio0.370.3879149
Slightly volatile
Days Sales Outstanding181204222
Slightly volatile
Book Value Per Share19.5619.07598.0569
Slightly volatile
Invested Capital0.00330.00350.0194
Slightly volatile
Average Payables2.2 M2.1 M535 K
Slightly volatile
Stock Based Compensation To Revenue1.881.9725.401
Slightly volatile
PB Ratio0.370.3879149
Slightly volatile
Payables Turnover0.270.25410.0705
Slightly volatile
Sales General And Administrative To Revenue16.3218.3619.988
Slightly volatile
Research And Ddevelopement To Revenue4.384.935.3684
Slightly volatile
Cash Per Share17.1913.31417.1129
Slightly volatile
Capex To Operating Cash Flow0.00240.00260.0155
Pretty Stable
Days Payables Outstanding1.4 K1.4 K8.1 K
Slightly volatile
Income Quality1.190.86570.9963
Slightly volatile
Intangibles To Total Assets0.230.35240.2278
Slightly volatile
Net Debt To EBITDA1.011.05995.4275
Slightly volatile
Current Ratio6.026.337137.5165
Pretty Stable
Tangible Book Value Per Share16.511.5726.8324
Slightly volatile
Receivables Turnover1.291.451.5784
Slightly volatile
Graham Number41.574.734517.0584
Slightly volatile
Shareholders Equity Per Share19.5619.07598.0569
Slightly volatile
Debt To Equity0.00330.00350.0194
Slightly volatile
Graham Net Net16.0311.10616.6416
Slightly volatile
Revenue Per Share0.360.350.0835
Slightly volatile
Interest Debt Per Share0.06330.06660.058
Slightly volatile
Debt To Assets0.0030.00310.0182
Slightly volatile
Price Book Value Ratio0.370.3879149
Slightly volatile
Days Of Payables Outstanding1.4 K1.4 K8.1 K
Slightly volatile
Ebt Per Ebit0.680.97050.9383
Slightly volatile
Company Equity Multiplier0.851.11621.0245
Pretty Stable
Long Term Debt To Capitalization0.01230.01380.0151
Slightly volatile
Total Debt To Capitalization0.00330.00350.019
Slightly volatile
Debt Equity Ratio0.00330.00350.0194
Slightly volatile
Quick Ratio5.96.215436.9499
Very volatile
Dividend Paid And Capex Coverage Ratio411391172
Slightly volatile
Net Income Per E B T0.791.02930.9839
Slightly volatile
Cash Ratio5.896.236.9375
Very volatile
Days Of Sales Outstanding181204222
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.00261.026
Slightly volatile
Price To Book Ratio0.370.3879149
Slightly volatile
Fixed Asset Turnover0.630.450.6967
Slightly volatile
Capital Expenditure Coverage Ratio411391172
Slightly volatile
Debt Ratio0.0030.00310.0182
Slightly volatile
Price Sales Ratio36.3938.312.2 K
Slightly volatile
Asset Turnover0.01020.00970.0023
Slightly volatile
Price Fair Value0.370.3879149
Slightly volatile
Operating Cycle181204222
Slightly volatile

Pasithea Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap17.7 M18.6 M42.2 M
Slightly volatile

Pasithea Fundamental Market Drivers

Cash And Short Term Investments16.3 M

Pasithea Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Pasithea Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pasithea Therapeutics income statement, its balance sheet, and the statement of cash flows. Pasithea Therapeutics investors use historical funamental indicators, such as Pasithea Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pasithea Therapeutics investors may use each financial statement separately, they are all related. The changes in Pasithea Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pasithea Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pasithea Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.6 M-2.7 M
Total Revenue559.5 K362.3 K
Cost Of Revenue648.5 K680.9 K
Stock Based Compensation To Revenue 1.97  1.88 
Sales General And Administrative To Revenue 18.36  16.32 
Research And Ddevelopement To Revenue 4.93  4.38 
Capex To Revenue(5.05)(5.31)
Revenue Per Share 0.35  0.36 
Ebit Per Revenue(27.41)(28.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Pasithea Stock

When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:
Check out the analysis of Pasithea Therapeutics Correlation against competitors.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.74)
Revenue Per Share
0.37
Quarterly Revenue Growth
14.981
Return On Assets
(0.33)
Return On Equity
(0.55)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.